Horizon Therapeutics (HZNP) reported Q3 EPS of $1.25, $0.19 better than the analyst estimate of $1.06. Revenue for the quarter came in at $925.4 million versus the consensus estimate of $893.7 million.
GUIDANCE:
Horizon Therapeutics sees FY2022 revenue of $3.59-3.61 billion, versus the consensus of $3.56 billion.